Chen An-Guo, Chen Dong-Sheng, Li Si, Zhao Le-le, Xiao Ming-Zhe
Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China.
Front Oncol. 2022 Mar 1;12:837219. doi: 10.3389/fonc.2022.837219. eCollection 2022.
Novel adjuvant strategies are needed to optimize outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). The adjuvant treatment of ROS Proto-Oncogene 1 () fusion-positive resected NSCLC is challenging because there is no curative confirmed randomized controlled trial. Next-generation sequencing (NGS) and immunohistochemistry (IHC) staining were performed on the biopsy sample. In this case, we identified a novel fusion in a resectable stage IIIA NSCLC patient. The patient received crizotinib as adjuvant treatment and achieved recurrence-free survival (RFS) for 29 months, without significant symptoms of toxicity. In this case, we report a novel fusion responding to crizotinib in a patient with lung adenocarcinoma, supporting the use of adjuvant treatment with the ROS1 inhibitor exerting clinical survival benefit in ROS1 fusion-positive resected NSCLC.
需要新的辅助治疗策略来优化早期非小细胞肺癌（NSCLC）患者完全手术切除后的治疗效果。ROS原癌基因1（）融合阳性的可切除NSCLC的辅助治疗具有挑战性，因为尚无经证实的治愈性随机对照试验。对活检样本进行了二代测序（NGS）和免疫组化（IHC）染色。在本病例中，我们在一名可切除的IIIA期NSCLC患者中发现了一种新的融合。该患者接受克唑替尼作为辅助治疗，实现了29个月的无复发生存期（RFS），且无明显毒性症状。在本病例中，我们报告了一例肺腺癌患者中对克唑替尼有反应的新型融合，支持在ROS1融合阳性的可切除NSCLC中使用ROS1抑制剂辅助治疗可带来临床生存获益。
